| 39.29 0.28 (0.72%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.27 | 1-year : | 48.75 |
| Resists | First : | 40.47 | Second : | 41.74 |
| Pivot price | 39.28  |
|||
| Supports | First : | 38.43 | Second : | 31.97 |
| MAs | MA(5) : | 38.94  |
MA(20) : | 39.71 |
| MA(100) : | 40.84 |
MA(250) : | 40.06 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 25.9 |
D(3) : | 17.6 |
| RSI | RSI(14): 40.6 |
|||
| 52-week | High : | 43.2 | Low : | 35.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BME ] has closed below upper band by 49.9%. Bollinger Bands are 5.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.54 - 39.69 | 39.69 - 39.84 |
| Low: | 38.72 - 38.91 | 38.91 - 39.09 |
| Close: | 38.99 - 39.28 | 39.28 - 39.56 |
BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.
Fri, 19 Apr 2024
Raymond James & Associates Acquires 1375 Shares of BlackRock Health Sciences Trust (NYSE:BME) - Defense World
Wed, 17 Apr 2024
Geneos Wealth Management Inc. Cuts Stake in BlackRock Health Sciences Trust (NYSE:BME) - Defense World
Tue, 16 Apr 2024
Raymond James Financial Services Advisors Inc. Has $898000 Position in BlackRock Health Sciences Trust (NYSE ... - Defense World
Sun, 14 Apr 2024
International Assets Investment Management LLC Invests $7.80 Million in BlackRock Health Sciences Trust (NYSE:BME) - Defense World
Thu, 28 Mar 2024
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions - Business Wire
Thu, 21 Mar 2024
Where are the Opportunities in (BME) - News Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 14 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 20.5 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 14 (K) |
| EPS | 1.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 42.18 |
| Profit Margin | 244.3 % |
| Operating Margin | 21.1 % |
| Return on Assets (ttm) | 0.2 % |
| Return on Equity (ttm) | 3.3 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.58 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -75.9 % |
| Operating Cash Flow | 32 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | 27.28 |
| PEG Ratio | 0 |
| Price to Book value | 0.93 |
| Price to Sales | 66.87 |
| Price to Cash Flow | 17.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|